Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5697004 | Brachytherapy | 2017 | 7 Pages |
Abstract
Of those men with World Health Organization pathologic grade Group 4 (Gleason score 8) prostate cancer and otherwise favorable prognostic features treated with androgen deprivation therapy and radiation therapy, longer OS was achieved when prostate brachytherapy was included, whether used alone or in combination with supplemental EBRT. In spite of these excellent outcomes, prostate brachytherapy utilization is declining in the United States.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Matthew W. Jackson, Arya Amini, Bernard L. Jones, Brian Kavanagh, Paul Maroni, Steven J. Frank, Usama Mahmood, Rajat J. Kudchadker, Thomas J. Pugh,